Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 11/20 | 0.55 |
| ▸ | CDK8 | P49336 | 11/20 | 0.55 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.35 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16827890 | 1.00 | CCNC (0.55) | CCNCCDK8SIRT3TDP1TRPM8 | |
| SCHEMBL9756928 | 0.81 | CCNC (0.50) | CCNCCDK8SIRT3TDP1 | |
| SCHEMBL9756927 | 0.81 | CCNC (0.50) | CCNCCDK8SIRT3TDP1 | |
| SCHEMBL3732406 | 0.76 | TRPM8 (0.48) | CCNCCDK8TRPM8NR4A2IP6K1 | |
| SCHEMBL19954281 | 0.76 | TRPM8 (0.48) | CCNCCDK8TRPM8NR4A2IP6K1 | |
| SCHEMBL1652393 | 0.76 | CCNC (0.48) | CCNCCDK8MEN1MAPTKMT2A | |
| SCHEMBL30034808 | 0.75 | CCNC (0.59) | CCNCCDK8NPC1RAB9A | |
| SCHEMBL22147601 | 0.75 | CCNC (0.39) | CCNCCDK8SIRT3TDP1 | |
| SCHEMBL24150009 | 0.74 | JUN (0.62) | CCNCCDK8TDP1TRPM8HTT | |
| SCHEMBL3275450 | 0.74 | JUN (0.62) | CCNCCDK8TDP1TRPM8HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277639-A1 | 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones | DOV PHARMACEUTICAL, INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277639-A1 | 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones | HTR1A, HTR2B, HTR4 | CCNC 1277/4885CDK8 1576/4885SIRT3 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.